HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Increased muscarinic cholinergic receptor density on CD4+ lymphocytes in progressive multiple sclerosis.

Abstract
We measured the density and affinity of muscarinic cholinergic receptors (MR) in 29 chronic progressive and ten stable multiple sclerosis (MS) patients and 27 control subjects using [3H]N-methyl-scopolamine. The density of MR on CD4+ lymphocytes was significantly higher in chronic progressive MS (CPMS) than in controls (7.9 +/- 0.7 vs. 4.5 +/- 0.4 fmol/10(6) cells, p less than 0.001). Stable patients did not differ significantly from control subjects. Receptors of the M1 subtype were measured on CD4+ lymphocytes of nine patients and seven controls with the selective antagonist [3H]methylpirenzepine: M1/total receptor ratio was 64.1% in CPMS and 81.2% in controls, suggesting a selective increase of M2-type MR in CPMS. The findings may relate to parasympathetic denervation hypersensitivity of lymphocytes or to lymphocyte activation which is known to be associated with increased MR number.
AuthorsB Anlar, J W Karaszewski, A T Reder, B G Arnason
JournalJournal of neuroimmunology (J Neuroimmunol) Vol. 36 Issue 2-3 Pg. 171-7 (Feb 1992) ISSN: 0165-5728 [Print] Netherlands
PMID1346264 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Receptors, Muscarinic
  • Scopolamine Derivatives
  • N-Methylscopolamine
Topics
  • Adult
  • CD4-Positive T-Lymphocytes (chemistry)
  • Female
  • Humans
  • Lymphocytes (chemistry)
  • Male
  • Middle Aged
  • Monocytes (chemistry)
  • Multiple Sclerosis (metabolism)
  • N-Methylscopolamine
  • Receptors, Muscarinic (analysis)
  • Scopolamine Derivatives (metabolism)
  • T-Lymphocytes, Helper-Inducer (chemistry)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: